BioMarin Pharmaceutical Inc. bought Zacharon Pharmaceuticals of San Diego for $10 million. Novato-based BioMarin (NASDAQ: BMRN) may pay more in the deal, depending on whether Zacharon hits certain milestones. Zacharon is working on treatments aimed at mucopolysaccharidosis disorders and also diseases like Tay Sachs and Sandhoff.